Immunoglobulin therapy improves mobility in phase 2/3 study

Phase 2a TREE study assesses safety and efficacy of leriglitazone

Company seeks new direction after negative CHMP opinion on KIZFIZO

CervoMed’s therapy demonstrates significant improvement in patients

Oxford Medical Products targets overweight individuals

FSCD therapy meets all endpoints in interim analysis

Scottish Medicines Consortium approves new option for mCRPC patients

NICE convenes third committee meeting for additional appraisal consideration

Octapharma supports NHS in building resilient supply chain

Cohort expansion phase commences with promising results